Total Payments
$77,431
2024 Payments
$29,726
Companies
16
Transactions
108
Medicare Patients
604
Medicare Billing
$88,801
Payment Breakdown by Category
Other$38,294 (49.5%)
Consulting$25,236 (32.6%)
Travel$10,521 (13.6%)
Food & Beverage$3,263 (4.2%)
Research$96.38 (0.1%)
Education$21.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,794 | 16 | 47.5% |
| Consulting Fee | $25,236 | 14 | 32.6% |
| Travel and Lodging | $10,521 | 32 | 13.6% |
| Food and Beverage | $3,263 | 43 | 4.2% |
| Honoraria | $1,500 | 1 | 1.9% |
| Unspecified | $96.38 | 1 | 0.1% |
| Education | $21.00 | 1 | 0.0% |
Payments by Type
General
$77,334
107 transactions
Research
$96.38
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $47,838 | 63 | $0 (2024) |
| Tempus AI, Inc | $9,582 | 10 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $5,245 | 4 | $0 (2024) |
| Foundation Medicine, Inc. | $4,805 | 4 | $0 (2020) |
| PFIZER INC. | $4,400 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,815 | 3 | $0 (2024) |
| Genentech USA, Inc. | $1,693 | 5 | $0 (2024) |
| G1 Therapeutics, Inc. | $1,500 | 1 | $0 (2021) |
| Genentech, Inc. | $135.52 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $104.95 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,726 | 38 | Lilly USA, LLC ($13,025) |
| 2023 | $32,157 | 41 | Lilly USA, LLC ($29,787) |
| 2022 | $124.29 | 1 | Lilly USA, LLC ($124.29) |
| 2021 | $3,346 | 4 | AstraZeneca Pharmaceuticals LP ($1,665) |
| 2020 | $4,927 | 7 | Foundation Medicine, Inc. ($4,805) |
| 2019 | $42.32 | 2 | Lilly USA, LLC ($23.76) |
| 2018 | $4,764 | 9 | Lilly USA, LLC ($4,639) |
| 2017 | $2,345 | 6 | PFIZER INC. ($2,180) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $121.55 | General |
| 09/03/2024 | Genentech, Inc. | Alecensa (Biological), Avastin, Columvi | Food and Beverage | In-kind items and services | $135.52 | General |
| Category: BioOncology | ||||||
| 08/30/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $122.93 | General |
| 08/29/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $415.06 | General |
| 08/29/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $349.60 | General |
| 08/29/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 07/22/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $87.10 | General |
| 06/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $45.75 | General |
| 06/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 05/31/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $96.38 | Research |
| Study: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 05/14/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 04/24/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| 04/23/2024 | Lilly USA, LLC | RETEVMO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: Oncology | ||||||
| 03/18/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $258.52 | General |
| Category: Oncology | ||||||
| 03/18/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $37.10 | General |
| Category: Oncology | ||||||
| 03/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $23.09 | General |
| Category: Oncology | ||||||
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological), LIBTAYO | Consulting Fee | Cash or cash equivalent | $2,352.00 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological), LIBTAYO | Consulting Fee | Cash or cash equivalent | $1,568.00 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological), LIBTAYO | Consulting Fee | Cash or cash equivalent | $1,176.00 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 02/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $96.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 110 | 179 | $47,720 | $18,790 |
| 2022 | 3 | 124 | 232 | $62,823 | $18,093 |
| 2021 | 4 | 160 | 354 | $98,907 | $26,194 |
| 2020 | 4 | 210 | 431 | $126,003 | $25,725 |
Total Patients
604
Total Services
1,196
Medicare Billing
$88,801
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 31 | 73 | $23,637 | $8,091 | 34.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 34 | $9,384 | $4,652 | 49.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 43 | $7,112 | $4,007 | 56.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 29 | $7,588 | $2,041 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 110 | $29,700 | $8,124 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 30 | 61 | $21,960 | $7,075 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 42 | 61 | $11,163 | $2,894 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 56 | 170 | $45,900 | $13,462 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 57 | $27,873 | $5,999 | 21.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 50 | 82 | $15,006 | $3,958 | 26.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 33 | $5,148 | $1,437 | 27.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $4,980 | $1,338 | 26.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 33 | 127 | $60,777 | $10,707 | 17.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 103 | $27,810 | $6,358 | 22.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 59 | 96 | $17,568 | $3,338 | 19.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 18 | 24 | $8,640 | $2,126 | 24.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 32 | 45 | $5,748 | $1,907 | 33.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 36 | $5,460 | $1,289 | 23.6% |
About Dr. Maurice Willis, MD
Dr. Maurice Willis, MD is a Hematology & Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942369319.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maurice Willis, MD has received a total of $77,431 in payments from pharmaceutical and medical device companies, with $29,726 received in 2024. These payments were reported across 108 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($36,794).
As a Medicare-enrolled provider, Willis has provided services to 604 Medicare beneficiaries, totaling 1,196 services with total Medicare billing of $88,801. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Saint Louis, MO
- Active Since 12/08/2006
- Last Updated 05/05/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942369319
Products in Payments
- JAYPIRCA (Drug) $11,344
- LIBTAYO (Biological) $5,245
- FOUNDATIONACT (Device) $4,805
- ALIMTA (Drug) $3,825
- BAVENCIO (Drug) $2,180
- IMFINZI (Biological) $1,665
- COSELA (Drug) $1,500
- RETEVMO (Drug) $201.73
- Alecensa (Biological) $135.52
- TECENTRIQ (Biological) $117.53
- OPDIVO (Biological) $104.95
- KEYTRUDA (Biological) $65.92
- SOMATULINE DEPOT (Drug) $63.90
- CYRAMZA (Drug) $23.76
- KRAZATI (Drug) $21.00
- KISQALI (Drug) $20.82
- IBRANCE (Drug) $19.91
- CALQUENCE (Drug) $14.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Saint Louis
Dr. Geoffrey Uy, Md, MD
Hematology & Oncology — Payments: $29,892
Hematology & Oncology $29,892
Dr. Jason Li, Md, MD
Hematology & Oncology — Payments: $22,919
Hematology & Oncology $22,919
John Finnie, Md, MD
Hematology & Oncology — Payments: $17,276
Hematology & Oncology $17,276
Dr. Atif Shafqat, M.d, M.D
Hematology & Oncology — Payments: $13,313
Hematology & Oncology $13,313
Dr. Shabbir Safdar, M.d, M.D
Hematology & Oncology — Payments: $12,290
Hematology & Oncology $12,290
Dr. Bryan Faller, Md, MD
Hematology & Oncology — Payments: $7,640
Hematology & Oncology $7,640